Mondobiotech targets phase III funding through increased capital


Stans – Swiss Mondobiotech Holding AG will finance clinical development of Mondobiotech’s Phase III programme in idiopathic pulmonary fibrosis through increasing its capital to CHF43m, selling 304,131 shares and three-year options in a rights offering. While the price per share will be CHF110, the options will be valued CHF40. According to Mondobiotech Imperial Fund, it expects to purchase more than 65% of the shares. Holders of every 215 subscription rights will be offered one new common share and one option entitling its holder to subscribe within an exercise period of 3 years for one new common share, worth CHF 150.00. Subscription rights will be traded on the Swiss Exchange from 26 January 2010 until on or about 9 February 2010 (ticker symbol: RARE1).



Basel/Hinxton (UK) – Two European teams have created huge repositories of cancer genomics data that help predict drug response. Swiss Novartis and the Boston-based Broad Institute have combined data obtained from large-scale...



London/Lausanne – The global private equity firm Celtic Therapeutic L.L.L.P. believes in the power of antibody-drug conjugates (ADCs). It is investing $50m in a new Switzerland-based company called ADC Therapeutics Sarl which...



Basel/Vienna - Following promising results from a Phase III study, Roche has submitted a regulatory application to EMA for subcutaneous Herceptin (trastuzumab) to treat HER2-positive breast cancer. Roche said subcutaneous...



After the US Food & Drug Administration forced Swiss generics giant Sandoz AG to update its production facilities in Quebec, there are now fears that supplies of some medicines could grow tight in Canada. The regulatory authority...



The hepatitis C space has seen a string of large deals in the last weeks that include a US$11bn buyout of Pharmasset by Gilead. Now Novartis is also trying to get in the game with the purchase of a global exclusive licence from...



Allschwil – Swiss Actelion Ltd. has strengthened its commercial offerings by securing rights in certain countries to Auxilium’s biotech drug Xiaflex for treating tissue buildup under the skin. The US pharma is to receive US$10m...



Zug – Life Sciences specialist HBM partners has raised €90m in the first close of its HBM BioCapital II fund, which will invest in revenue-generating companies in the pharmaceuticals, medical device and diagnostics sectors....



Stans – Mondobiotech, a drug discovery company in troubled waters, could soon be under Italian ownership: The Swiss biotech announced it has entered into exclusive negotiations with Milan-based provider of pharmaceutical and...

Displaying results 1 to 10 out of 276

1-10 Next >

© 2007-2014 BIOCOM


Product of the week



All Events

Current issue

All issues